GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT01542242

TerminatedPhase 4

Liraglutide Use in Prader-Willi Syndrome

Lead sponsor

Vancouver General Hospital

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Hypothalamic / syndromic obesity, Type 2 diabetes

Key I/E criterion

•Male

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01542242

Org study IDPWS.VGH.UBC

Timeline

Milestones

Study first posted2012-03-02estimated

Last update posted2015-12-09estimated

Study start2012-02 (month precision)

Primary completion2013-03actual (month precision)

Study completion2013-03actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Hypothalamic / syndromic obesityType 2 diabetes

Eligibility

Who can enroll

Minimum age19 Years

SexMale

Healthy volunteersAccepted

Inclusion criteria

•Prader Willi Syndrome, Diabetes Type 2

Exclusion criteria

•Previous or family history of Medullary Carcinoma of the Thyroid or multiple endocrine neoplasia syndrome.

•Subjects with acute or chronic Pancreatitis

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Glycemic / diabetes

Cardiometabolic biomarkers

Weight & body composition

3 endpoints

Secondary/protocol endpoint

Body Weight (kg)

Time frame:Change from baseline in body weight at 12 months

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Hip Circumference (cm)

Time frame:Change from baseline in hip circumference at 12 months

change from baseline, improvement

Secondary/protocol endpoint

Total Body Adipose Tissue Distribution (whole body Computed Tomography)

Time frame:Change from baseline in total body adipose tissue distribution at 12 months

change from baseline, improvement

Glycemic / diabetes

3 endpoints

Primary/protocol endpoint

Hemoglobin A1C

Time frame:Change from baseline in A1C at 12 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Fasting Blood Glucose (mmol/L)

Time frame:Change from baseline in fasting blood glucose at 12 months

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Fasting Blood Insulin level

Time frame:Change from baseline in fasting blood insulin at 12 months

change from baseline, improvement

Cardiometabolic biomarkers

1 endpoint

Secondary/protocol endpoint

Fasting Lipid Profile

Time frame:Change from baseline in fasting lipid profile at 12 months

change from baseline, improvement

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome.
The Journal of clinical endocrinology and metabolism2011 Aug (month)PMID21632815doi:10.1210/jc.2011-0038via CT.gov background
Liraglutide therapy in Prader-Willi syndrome.
Diabetic medicine : a journal of the British Diabetic Association2011 Jun (month)PMID21388446doi:10.1111/j.1464-5491.2011.03280.xvia CT.gov background

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.